Bladder Cancer Market Overview
Bladder Cancer Market Size was valued at USD 5.5 Billion in 2022. The Bladder Cancer market industry is projected to grow from USD 5.8 Billion in 2023 to USD 8.2 Billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.60% during the forecast period (2023 - 2030). The rising cost of healthcare, rising burden of bladder disorders, and rising public awareness of bladder diseases and treatment options, are the key market drivers enhancing the market growth.
Bladder Cancer Market Trends
The growing awareness of bladder disorders and accessible therapeutics is propelling market expansion.
Due to rising healthcare costs, rising healthcare expenditures, and increasing incidence of bladder cancer, the market for bladder cancer treatments and diagnostics may experience substantial expansion. For example, the World Coalition of Bladder Cancer Patients has declared March 2022 to be "Don't Go Red" Month for Bladder Cancer Awareness in an effort to increase public knowledge of the signs. harbingers and symptoms of the disease. Early detection is essential to improve long-term survival and quality of life. During the forecast period, these activities are expected to drive the growth of the market. Moreover, the rise of the market over the projected period is supported by the rising prevalence of bladder cancer globally. For example, according to statistics from the World Cancer Watch 2020, prostate and bladder cancers are two of the ten cancers with the highest incidence rates in the world. According to the same source, there will likely be 573,278 new cases of bladder cancer and 1,414,259 new cases of prostate cancer in both genders in 2020. Global cancer incidence drives the market over time .
Product launches and mergers and acquisitions by significant industry competitors are also expected to drive the market. Merck, known as MSD outside the US and Canada, announced an August 2021 label update for KEYTRUDA, an anti-PD-1 medication, for urothelial cancer.
Bladder cancer is the world's tenth most common cancer. The American Cancer Society predicts that around 83,730 Americans will be diagnosed with bladder cancer in 2021. Furthermore, $1.18 million in philanthropic contributions and institutional investments were utilised to construct bladder cancer research facilities at Birmingham University in the United Kingdom. Another trend supporting market expansion during the forecast period is an ageing population, which is more prone to bladder cancer. The elderly are more vulnerable to urinary tract cancer because their immune cells that fight malignant bladder tissue are diminished. According to the American Society of Clinical Oncology (ASCO), 90% of bladder cancer patients were over the age of 55 in January 2021. Both smoking and occupational exposure, according to the American Cancer Society, can contribute to the development of bladder cancer. As a result, the Bladder Cancer market is growing.
Bladder Cancer Market Segment Insights:
Bladder Cancer Type Insights
Transitional cell carcinoma, invasive bladder cancer, superficial bladder cancer, adenocarcinoma, and other uncommon forms are included in the Bladder Cancer Market segmentation. In 2022, the transitional cell carcinoma segment dominated the global market. As a result, both affluent and poor countries' healthcare infrastructures have improved. The worldwide bladder cancer treatments market is expected to develop rapidly in the superficial bladder cancer category during the projected period. The growth of this sector is attributable to increased awareness of superficial bladder disease, improved healthcare infrastructure in both developed and developing countries, and technological improvements.
Bladder Cancer Treatment Insights
The Bladder Cancer Market is divided into therapeutic categories, which include chemotherapy, radiation therapy, immunotherapy, radical cystectomy, and others. In 2022, the chemotherapy category will dominate the global market. This is due to the fact that a variety of chemotherapeutic therapies will be available in 2021. Immunotherapy, on the other hand, is predicted to have rapid growth in the bladder cancer therapy market. The increasing prevalence of the targeted conditions, the growing preference for immunotherapy over conventional therapies, and the expanding demand for monoclonal antibodies and biosimilars are the primary drivers of immunotherapy segment growth.
Bladder Cancer Diagnosis Insights
Based on diagnosis, the Bladder Cancer Market segmentation covers urine lab tests, cystoscopy, biopsy, imaging tests, and others. In 2022, the Cystoscopy segment led the Bladder Cancer Market. During a cystoscopy, the bladder and urethra's interior are examined using a telescope. A cystoscope is a specialist endoscope that is delivered via the urethra into the bladder to perform a direct visual inspection of the urothelium. Cystoscopy is inexpensive. The increased prevalence of bladder cancer, as well as product launches by leading market players, all contribute to the expansion of this market segment.
Bladder Cancer End User Insights
End-user segmentation in the Bladder Cancer Market comprises hospitals, clinics, cancer care centres, and others. In 2022, the hospital sector dominated the Bladder Cancer Market. This is due to the rising use of technologically advanced treatment choices in hospitals throughout the world.
Bladder Cancer Regional Insights
By region, the study provides market insights across North America, Europe, Asia-Pacific, and Rest of the World. The bladder cancer market in North America led this market in 2022 (45.80%). This is a result of the region's expanding R&D activities and well-established healthcare infrastructure. The existence of numerous biologics and biopharmaceutical companies is another factor that has contributed to the size and skyrocketing growth of the bladder cancer therapeutics and diagnostics market. In the United States, there are approximately 81,180 new cases of bladder cancer in 2022 (61,700 in men and 19,480 in women), according to January 2022 statistics from the American Cancer Society. Hence, the need for bladder cancer detection and treatment is expected to increase as its prevalence rises, supporting the expansion of the market. Additionally, the US bladder cancer market held the largest market share, and the Canadian bladder cancer market was the fastest growing market in North America.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
The European bladder cancer market accounted for the healthy market share in 2022. This is due to the significant increase in bladder cancer cases in the European region. Bladder cancer is ranked as the 11th most dangerous disease in the UK with around 10,300 cases reported in the country between 2016 and 2018. Additionally, the German bladder cancer market held the largest share market share, and the UK bladder cancer market was the fastest growing market in the European region
The bladder cancer market in Asia Pacific is expected to register significant growth from 2023 to 2030. This growth is mainly attributed to increased awareness of bladder diseases and new diagnostic and therapeutic approaches. Major market players are investing heavily in Asia as they believe it is a lucrative market for bladder cancer and hence the market is growing there. With each passing year, the number of bladder cancer diagnoses is increasing significantly in the Asia-Pacific region. In 2018, there were 10,231 deaths and 18,921 cases of bladder cancer in India. Additionally, the Chinese bladder cancer market held the largest market share and the Indian bladder cancer market was the fastest growing market in the Asia-Pacific region.
Bladder Cancer Key Market Players & Competitive Insights
The major market players are investing heavily in research and development to expand their type ranges which will help the bladder cancer market grow even further. Market players are also undertaking various strategic activities to expand their global footprint, with significant developments in the market including new type launches, contractual agreements, mergers and acquisitions, larger investments, and collaboration with others organizations. To grow and survive in a more competitive and rising market climate, the bladder cancer industry must offer cost-effective items.
Local manufacturing to minimize operational cost is one of the major business tactics used by manufacturers in the global Bladder Cancer industry to benefit the customers and increase the market sector. In recent years, the bladder cancer industry has provided some of the greatest benefits to medicine. Major Bladder Cancer Market Players include AstraZeneca Plc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., Novartis International AG, Pfizer Inc., Sanofi S.A. , Merck & Co. Inc., Accord Healthcare and Bedford Lab are trying to increase market demand by investing in type research and development.
Pharmaceuticals of all kinds are discovered, developed, produced and sold by Astellas Pharma Inc (Astellas). Marketed therapies for the treatment of various urological disorders, infectious diseases, cancer, nephrology and metabolic diseases, immunodeficiency diseases and transplantation are included in the Company's product portfolio. Its pipeline includes drug candidates for the treatment of various diseases, including acute myeloid leukemia (AML), urothelial cancer, gastric cancer, gastroesophageal junction cancer, anemia related to chronic renal failure (CRI) in dialysis patients, rheumatoid arthritis and non-dialysis patients. the patients. With the help of a network of subsidiaries and affiliates, it operates in America, Australia, Europe, Asia and Oceania. Tokyo, Japan is the headquarters of Astellas. Preliminary results from Cohort H of the EV-103 study, which is investigating PADCEV (enfortumabvedotin-jeff) as monotherapy in patients with muscle-invasive bladder cancer (MIBC) who are not eligible cisplatin therapy, were published in February 2022 by Astellas Pharma Inc. and Seagen Inc.
A biopharmaceutical company called Merck & Co Inc (Merck) is engaged in the discovery, development, production and marketing of prescription drugs, biological therapies, vaccines and animal health products. It provides prescription products for the treatment of diseases such as diabetes, cancer, immunological diseases, cardiovascular diseases and cancer. Keytruda (pembrolizumab), which is used to treat urothelial carcinoma, received U.S. Food and Drug Administration approval in August 2021, according to Merck, a leading global biopharmaceutical company.
Key Companies in the Bladder Cancer market include
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Celgene Corporation
- Eli Lilly and Company
- Hoffmann-La Roche AG
- GlaxoSmithKline Plc.
- Novartis International AG
- Pfizer Inc.
- Sanofi S.A.
- Merck & Co. Inc.
- Accord Healthcare
- Bedford Lab
Bladder Cancer Industry Developments
July 2022:Using its ClarityDX diagnostic technology, Nanostics Inc. has initiated a prospective clinical research to evaluate ClarityDX Bladder, a novel and less invasive bladder cancer diagnostic test. In partnership with DynaLIFE Medical Labs and the Alberta Prostate Cancer Research Initiative (APCaRI) at the University of Alberta,
Bladder Cancer Market Segmentation:
Bladder Cancer Type Outlook
- Transitional Cell Carcinoma
- Invasive Bladder Cancer
- Superficial Bladder Cancer
- Adenocarcinomax
- Other Rare Types
Bladder Cancer Treatment Outlook
- Chemotherapy
- Radiation Therapy
- Immunotherapy
- Radical Cystectomy
- Others
Bladder Cancer Diagnosis Outlook
- Urine Lab Tests
- Cystoscopy
- Biopsy
- Imaging Test
- Others
Bladder Cancer End User Outlook
- Hospital
- Clinic
- Cancer Care Centers
- Others
Bladder Cancer Regional Outlook
- North America
- US.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
Latin America